---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-077126"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2023-06-30T23:59:59+00:00"
generated_at: "2026-06-13T14:11:09.627906+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# BioXcel shareholders elect three Class II directors, ratify Ernst & Young as auditor

## Summary
- Elected directors: Sandeep Laumas (12,360,360 for, 8,899,824 withheld), Michael Miller (21,149,269 for, 110,915 withheld), Michal Votruba (18,041,794 for, 3,218,390 withheld).
- Ratified Ernst & Young as auditor for FY2023 with 24,849,840 for, 51,173 against, 7,597 abstained.
- Turnout was 24,908,610 shares (85.42% of outstanding) as of April 27, 2023 record date.

## SEC filing metadata
- accession: 0001104659-23-077126
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2023-06-30T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465923077126/0001104659-23-077126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465923077126/tm2320221d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-077126
- JSON: https://secwatch.observer/filing/0001104659-23-077126.json
- Plain text: https://secwatch.observer/filing/0001104659-23-077126.txt

## Key facts
- Shareholder Votes
  BioXcel Therapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. at the 2023-06-26 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-26
  source text: Item 2 — Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 24,849,840 51,173 7,597 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720893/000110465923077126/0001104659-23-077126-index.htm
- Shareholder Votes
  BioXcel Therapeutics, Inc. shareholders approved Election of three Class II directors for a term of office expiring on the date of the annual meeting of stockholders in 2026 and until his successor has been duly elected and qualified. at the 2023-06-26 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-26
  source text: NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Sandeep Laumas, M.D. 12,360,360 8,899,824 3,648,426 Michael Miller 21,149,269 110,915 3,648,426 Michal Votruba, M.D. 18,041,794 3,218,390 3,648,426
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720893/000110465923077126/0001104659-23-077126-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.